MEIBO (perfluorohexyloctane): a novel approach to treating dry eye disease

• Published in: Annals of medicine and surgery 2024-09, Vol.86 (9), p.5292-5298
• Main Authors: Azhar, Ayesha, Taimuri, Muskan A, Oduoye, Malik Olatunde, Sumbal, Anusha, Sheikh, Ayesha, Iqbal, Amna, Ikram, Areeba, Waqar, Eisha
• Format: Article
• Language: English
• Subjects: Reviews
• ISSN: 2049-0801; 2049-0801
• DOI: 10.1097/MS9.0000000000002322

Dry eye disease (DED) or keratoconjunctivitis sicca (KCS) is a multifactorial disease that classically develops due to the hyperosmolarity of the tear film. Categorically divided into two types, based on decreased production and increased evaporation of the tear film, DED begins with a spectrum of nonspecific symptoms like pruritus, redness, burning and discomfort, progressively leading to stringy mucus eye discharge, photophobia, twitching, visual fluctuations, and punctate epithelial lesions. This disease has numerous treatment options, including medications, artificial tear inducers, and surgical manoeuvres that prevent water loss from the tear film. However, each of these treatment options has its limitations. The Food and Drug Administration (FDA) has approved another intervention, Meibo (perfluorohexyloctane), as a choice of management for dry eye disease. With its shielding action on the ocular surface, Meibo (perfluorohexyloctane) reduces desiccation stress-induced ocular damage, making it highly specific for treating DED. Available in an eye drop formulation of perfluorohexyloctane (PFHO), these drops can reduce saline evaporation by up to 80%. The methods we used for this analysis are literature searches from PubMed, Medline and Google Scholar. This study aims to scour varying differentials of DED, its aetiology, general interventions, the latest refinements, and clinical efficacy, safety, and trials associated with Meibo (perfluorohexyloctane) in the management of DED.